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Pembrolizumab is a new monoclonal antibody
chemotherapeutic agent that binds to the pro-
grammed cell deathe1 receptor and decreases the
down-regulation of lymphocytes in patients treated
for metastatic melanoma.1 Because this drug is
relatively new, little is known about its effect on
cutaneous melanoma metastases. We report a case
detailing the unexpected keratoacanthomalike
appearance of melanoma metastases in a patient
receiving pembrolizumab.
REPORT OF A CASE
A 52-year-old man with BRAF-negative metastatic
melanoma presented to the dermatology clinic for
evaluation of rapidly growing lesions on his scalp,
chest, mons pubis, and right lateral trunk 1 month
after starting pembrolizumab (2 mg/kg). Eighteen
months before presentation, he had nodular
melanoma (Breslow depth, 4.7 mm) diagnosed on
his left buttock. He underwent wide local excision
and sentinel lymph node biopsy, whichwas positive.
Magnetic resonance imaging and positron emission
tomography scans were negative for metastatic
disease. His disease remained quiescent until
14 months after his initial diagnosis when he noted
2 new scalp lesions, which were found to be
melanoma metastases. Repeat imaging was negative
for systemic disease, and the patient was started on
ipilimumab. Unfortunately, his ipilimumab course
was complicated by hypophysitis, requiring predni-
sone therapy and discontinuation of ipilimumab.the University of Iowa Carver College of Medicinea and
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small red papules that remained stable in size.
During his 6 weeks of prednisone therapy, these
lesions grew rapidly. Ipilimumab therapy was
subsequently discontinued, he transitioned from
prednisone to maintenance hydrocortisone, and he
started on pembrolizumab. Shortly after starting
pembrolizumab, the patient’s lesions became painful
and developed a domelike appearance, prompting
his presentation in our clinic after completion of his
second cycle.
Examination found 4 pink papulonodules with
central hyperkeratotic cores on the scalp, chest,
midback, and mons pubis ranging in size from
0.9 to 1.3 cm that were consistent with keratoacan-
thomas (Fig 1).
Histopathology of these lesions found a
dome-shaped, dermal melanocytic proliferation
with an overall bland architecture at low power. At
higher power, the melanocytes showed atypia with
numerous mitoses. There was an associated
lymphocytic inflammatory infiltrate at the base of
the lesions (Fig 2).
The patient completed 2 more cycles of
pembrolizumab after the diagnosis of these lesions
and new skin lesions continued to develop and were
concerning for metastases. Positron emission
tomography scan several weeks after he was seen
by the dermatology department found widely
progressive disease, and he was started on temozo-
lomide with subsequent complete resolution of
disease.JAAD Case Reports 2016;2:247-9.
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Fig 1. Representative clinical images of keratoacanthomalike melanoma metastases on the left
upper chest (1.2 cm) (A) and upper back (0.9 cm) (B).
Fig 2. Histopathology of the dermal melanoma metastases. A, On low power, there is a
well-circumscribed, dome-shaped lesion with lymphocytes at the base. B, Higher power
showed atypical melanocytes with mitoses (A and B, Hematoxylin-eosin stain; original
magnifications: A, 34; B, 340.)
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Pembrolizumab is an antibody that inhibits
the programmed cell deathe1 receptor, a surface
receptor on lymphocytes that down-regulates the
activation of T cells.1 It was approved by the US Food
and Drug Administration via the Fast Track
Development Program for use in melanoma in
September 2014. Early research found pembrolizu-
mab to be effective in prolonging progression-free
and overall survival in melanoma patients and be
more effective and less toxic than ipilimumab.2
Despite its apparent efficacy, little is known about
the adverse effects of pembrolizumab. The few
reported adverse effects include autoimmune
conditions, such as bullous pemphigoid and
autoimmune myocarditis.3,4 The development of
these autoimmune conditions may be related
pembrolizumab’s action of disinhibiting the activa-
tion of T cells, which increases the risk of recognition
of self-antigens and decreases self-tolerance.
We report a clinically misleading presentation
of pembrolizumab’s effects on dermal melanomametastases. Our patient’s most recent metastases
developed while he was immunosuppressed
with prednisone, and the lesions were painful, a
symptom not usually seen with dermal melanoma
metastases. We hypothesize that immune activation
during pembrolizumab therapy and the resulting
tumor-associated lymphocytes confined the tumors
to the dermis, aided in tumor shrinkage, and
caused the dome-shaped architecture of the lesions.
The inflammatory component of the immune
response was also likely responsible for the pain
the patient reported. This case highlights the
potentially unusual clinical appearance of dermal
melanoma metastases associated with treatment
using pembrolizumab.
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